Cereno Scientific presents positive results from the first clinical study with CS1
The analysis of Cereno Scientific’s first clinical study with CS1 has been concluded, with positive results regarding safety, pharmacokinetic properties and effect on biomarker for the risk of thrombosis.“It is very satisfying for us to have demonstrated the expected properties for CS1 in a clinical study as well. With this convincing safety profile, and favourable data as regards the release profile and effects on the PAI-1 biomarker, we feel comfortable in pursuing development forward and defining the continued clinical programme,” says Cereno Scientific’s CEO Sten R. Sörensen.The study